Remove Ethics Remove Finance Remove Pharmaceuticals
article thumbnail

Conflict-of-Interest Rules Are Holding Back Medical Breakthroughs

Harvard Business Review

Equally troublesome, almost all policies focus exclusively on payments and finances but ignore the powerful influence of careerism and other non-financial motives that may compromise objectivity far more than financial incentives. For academics, publishing and obtaining grants are key to promotion and career advancement.

article thumbnail

Why Are Some Sectors (Ahem, Finance) So Scandal-Plagued?

Harvard Business Review

initiative — prohibitions against off-label marketing under the False Claims Act — swept through the pharmaceutical industry. The most notable was Fannie Mae's $10.8 billion restatement. In another instance, a new enforcement. The largest payments were from Pfizer ($2.3 billion) and GlaxoSmithKline ($3 billion).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Merck Is Trying to Keep Disrupters at Bay

Harvard Business Review

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products. Experimentation is vital.

article thumbnail

The “Maximize Profits” Trap in Decision Making

Harvard Business Review

Imagine, for example, that you’re a pharmaceutical CEO deciding whether to recall a new drug. In these cases, running the numbers and grasping what they tell you is important, but it isn’t enough. With gray area problems, you have to look hard at the economics and look past the economics. How should you make this decision?

ROI 8
article thumbnail

The Tempting of Rajat Gupta

Harvard Business Review

Among McKinsey's biggest clients in the 1990s were pharmaceuticals and financial-services companies. The strategy firms saw some of their best talent head off to startups, which promised untold riches, at least until the Dotbust of 2000, and to Wall Street or Greenwich or wherever the racier genii of modern finance ply their trade.

article thumbnail

Introducing 100 Coaches: Pay It Forward Champions

Marshall Goldsmith

Darek Lenart – Senior VP HR, Finance MasterCard. Former HR director with Pepsi Central Eastern Europe, and gained HR expertise at PLIVA Pharmaceutical Company (now part of Teva Group). Sanyin Siang – Executive Director of the Duke University Fuqua/Coach K Center on Leadership & Ethics (COLE). Author: The Launch Book.